1. Expression of MicroRNA-155 is Downregulated in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B Patients
    Su-Lin Yu et al, 2016, Hepat Mon CrossRef
  2. MicroRNA-mediated interactions between host and hepatitis C virus
    Hu Li, 2016, WJG CrossRef
  3. Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes
    Zhicheng Fan et al, 2017, Microbial Pathogenesis CrossRef
  4. Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models
    Sarah E. Riad et al, 2018, Front. Genet. CrossRef
  5. null
    S. Georgiou et al, 2019 CrossRef
  6. An update on the role of miRNA-155 in pathogenic microbial infections
    Fu-Rong Zeng et al, 2015, Microbes and Infection CrossRef
  7. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma
    Amit Ghosh et al, 2016, Int. J. Cancer CrossRef
  8. Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
    Aiman Obed et al, 2016, Am J Case Rep CrossRef
  9. null
    Ewelina Kałużna, 2016 CrossRef
  10. null
    Ewelina Kałużna, 2017 CrossRef
  11. In vitro knock‐out of miR‐155 suppresses leukemic and HCV virus loads in pediatric HCV‐4–associated acute lymphoid leukemia: A promising target therapy
    Safaa S. Hassan et al, 2019, J Cell Biochem CrossRef
  12. MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection
    Amal Ahmed Mohamed et al, 2020 CrossRef
  13. MicroRNA-155 and antiviral immune responses
    Abdollah Jafarzadeh et al, 2021, International Immunopharmacology CrossRef
  14. Micro-Players of Great Significance—Host microRNA Signature in Viral Infections in Humans and Animals
    Ewa Ostrycharz et al, 2022, IJMS CrossRef
  15. The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis.
    Xinyan Xue et al, 2023, Int Immunopharmacol CrossRef